In a crossover trial evaluating semaglutide versus placebo as an add-on to automated insulin delivery therapy in adults with type 1 diabetes, the use of semaglutide was associated with an increased percentage of time spent within the target glucose range, along with reduced insulin requirements.
- Melissa-Rosina Pasqua
- Michael A. Tsoukas
- Ahmad Haidar
